Updated results of the phase I, open-label study of BCMA/CD19 dual-targeting, fast CAR-T GC012F for patients with r/r MM, were reported recently by Juan Du, Wei-Jun Fu, and Hua Jiang (92). Here, CD19 is linked to Miyoshi myopathy.